What does TWi Biotechnology, Inc. do?

TWi Biotechnology, Inc. (6610.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6610.TWO's market cap?

TWi Biotechnology, Inc. (6610.TWO) has a market capitalization of approximately $6.61 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6610.TWO pay a dividend?

No — TWi Biotechnology, Inc. (6610.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6610.TWO profitable?

TWi Biotechnology, Inc. (6610.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6610.TWO

TWi Biotechnology, Inc.

TWO·Biotechnology · Healthcare

NT$32.15NT$0.40+1.26%

Market capNT$6.61B·Aug 26 6:59 AM UTC

Price Chart

NT$32.15+NT$0.40 (+1.26%)today

+80.01%CAGR +12.48%

Select date range

FromTo

Dec 27, 2016Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

6610.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$0.00

Net Income−NT$299.40M

Net Margin—

Operating Cash Flow−NT$370.61M

Capital ExpendituresNT$387.00K

Free Cash Flow−NT$370.99M

Return on Equity−62.7%

Return on Invested Capital−38.5%

Net CashNT$110.25M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6610.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6610.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6610.TWO and 80,000+ other tickers.

About TWi Biotechnology, Inc.

TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and…

CEO: Chen-En Tsai
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 27
Website: www.twibiotech.com

Peers

Peers Tab

6885.TWO

BRIM Biotechnology, Inc.

Cap

NT$2.8B

6657.TW

Energenesis Biomedical CO.,LTD.

Cap

NT$2.7B

6926.TWO

Shine-On BioMedical Co.,Ltd.

Cap

NT$3.1B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6610.TWO

What does TWi Biotechnology, Inc. do?: TWi Biotechnology, Inc. (6610.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6610.TWO's market cap?: TWi Biotechnology, Inc. (6610.TWO) has a market capitalization of approximately $6.61 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6610.TWO pay a dividend?: No — TWi Biotechnology, Inc. (6610.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6610.TWO profitable?: TWi Biotechnology, Inc. (6610.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.